Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
This is an randomized, controlled, multicenter phase 3 clinical trial. The purpose of this study is to evaluate the efficacy and safety of single-agent capecitabine as adjuvant chemotherapy in locoregionally advanced…
- Trial name
- CAN (NCT02958111)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 406 people
- Sponsor
- Sun Yat-sen University
Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
The performance of the predictive models for the occurrence and severity of oropharyngeal mucositis established using either oral cavity contouring method or mucosa surface contouring method was unsatisfactory in nasopharyngeal…
- Trial name
- NCT06308328
- Where
- 10 sites in China
- Volunteers
- 718 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group
Nasopharyngeal Carcinoma
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for nasopharyngeal carcinoma.
- Trial name
- NCT02523430
- Testing
- interventional therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Nasopharyngeal Carcinoma
Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging
Nasopharyngeal cancer is common in China, Southeast Asia, and North Africa, and is usually associated with Epstein-Barr virus (EBV) infection.
- Trial name
- NCT06129201
- Testing
- Tongue image
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer
- Trial name
- NCT07063212
- Testing
- Sacituzumab Govitecan, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mouth Cancer
Wild Type p53 Adenovirus for Oral Premalignancies
Primary Objectives: 1. To determine the maximum tolerated dose and transduction efficiency of adenoviral mediated wild type p53 gene transfer in premalignancies of the upper aerodigestive tract. 2.
- Trial name
- NCT00410865
- Testing
- INGN 201
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis，safety was also evaluated.
- Trial name
- NCT03904225
- Testing
- Tegafur-Gimeracil-Oteracil
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Neoplasms
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
Among all the head and neck tumors, nasopharyngeal carcinoma (NPC) has a high tendency of recurrence and metastasis. For the advanced NPC patients, chemoradiotherapy is the main way of treatment.
- Trial name
- NCT02444949
- Testing
- endostar, intensity modulated radiation, cisplatin
- Volunteers
- 75 people
- Sponsor
- China Three Gorges University, Yichang, China
Nasopharyngeal Neoplasms
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
This study is a phase II clinical study. Recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC) were treated by cisplatin and 5-fluorouracil with Sorafenib…
- Trial name
- NCT00747799
- Testing
- Sorafenib plus Cisplatin and 5-fluorouracil
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03058432
- Testing
- Radiotherapy alone, Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
This is an opene-label, single center, randomized prospective pilot study to compare the efficacy of weekly versus triweekly fosaprepitant regimens for the prevention of nausea and emesis during concurrent chemoradiotherapy for…
- Trial name
- NCT04636632
- Testing
- fosaprepitant
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug…
- Trial name
- NCT07781358
- Testing
- Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hongmeng Yu
Head and Neck Neoplasms
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Treatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy.
- Trial name
- UPFRONT-NECK (NCT02918955)
- Testing
- up-front neck dissection, radiotherapy, Chemotherapy (Cisplatin)
- Where
- 2 sites in Switzerland
- Volunteers
- 65 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 202 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
TPF, Immunotherapy
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NPC is one of the most common malignant tumors in the head and neck region of China. Currently, the main treatment regimen for LA-NPC is radical concurrent chemoradiotherapy combined with induction or adjuvant chemotherapy.
- Conditions
- TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
- Trial name
- NCT06781112
- Testing
- albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Weiwei Zhang
Nasopharyngeal Carcinoma (NPC)
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07797881
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Neoplasms, Herpesvirus 4, Human
Environmental and Genetic Determinants of NPC
Background: Nasopharyngeal carcinoma (NPC) a common malignant tumor in southern China and Southeast Asia. Infection with Epstein-Barr virus is believed to be necessary for the development of NPC; non-viral environmental factors…
- Trial name
- NCT01257100
- Where
- 6 sites in Taiwan
- Volunteers
- 3,500 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.
- Trial name
- NCT02328261
- Testing
- Icotinib
- Volunteers
- 66 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.